Covered recipient · General Payments record
HEATHER N LONGVAL
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,777.83
- Reported across 135 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $496.81 | 33 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $143.82 | 14 |
| Acerta Pharma LLC | $81.76 | 4 |
| ABBVIE INC. | $68.89 | 3 |
| Novo Nordisk AS | $56.99 | 4 |
| Xeris Pharmaceuticals, Inc. | $46.77 | 2 |
| Seqirus USA Inc | $35.38 | 2 |
| E.R. Squibb & Sons, L.L.C. | $28.84 | 2 |
| ABIOMED | $19.88 | 1 |
| Lilly USA, LLC | $14.48 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (33)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.26 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899469 | CMS |
| ABBVIE INC. | $26.79 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899471 | CMS |
| ABBVIE INC. | $17.84 | 11/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104899473 | CMS |
| ABIOMED | $19.88 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142266026 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.44 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105762440 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.57 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105307117 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.84 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105651306 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.91 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105759389 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.38 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101234389 | CMS |
| E.R. Squibb & Sons, L.L.C. | $15.46 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101234439 | CMS |
| Lilly USA, LLC | $14.48 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134980240 | CMS |
| Novo Nordisk Inc | $14.77 | 02/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096991535 | CMS |
| Novo Nordisk Inc | $13.91 | 04/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097560476 | CMS |
| Novo Nordisk Inc | $13.85 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097473817 | CMS |
| Novo Nordisk Inc | $14.46 | 11/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096969807 | CMS |
| PFIZER INC. | $11.91 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130885416 | CMS |
| PFIZER INC. | $8.89 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132039631 | CMS |
| PFIZER INC. | $14.49 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131223956 | CMS |
| PFIZER INC. | $4.96 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132052838 | CMS |
| PFIZER INC. | $6.62 | 05/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132049834 | CMS |
| PFIZER INC. | $6.93 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132044556 | CMS |
| PFIZER INC. | $13.08 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131474841 | CMS |
| PFIZER INC. | $2.58 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132046152 | CMS |
| PFIZER INC. | $10.53 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132066063 | CMS |
| PFIZER INC. | $15.69 | 07/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131754566 | CMS |
| PFIZER INC. | $14.00 | 08/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131871529 | CMS |
| PFIZER INC. | $6.95 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132121744 | CMS |
| PFIZER INC. | $16.98 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132083298 | CMS |
| PFIZER INC. | $10.21 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131149994 | CMS |
| Seqirus USA Inc | $18.64 | 03/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125632276 | CMS |
| Seqirus USA Inc | $16.74 | 12/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125632326 | CMS |
| Xeris Pharmaceuticals, Inc. | $24.27 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144596278 | CMS |
| Xeris Pharmaceuticals, Inc. | $22.50 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144596280 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.